Analysis of U.S. Drug Patent 9,561,197
U.S. Patent 9,561,197, granted on February 7, 2017, to Pfizer Inc., covers a pharmaceutical composition containing certain antibodies and their use in treating specific medical conditions. The patent's claims focus on antibodies that bind to and inhibit the activity of programmed cell death protein 1 (PD-1) or its ligand (PD-L1). This mechanism is central to cancer immunotherapy, where these antibodies aim to release the brakes on the immune system, enabling it to attack cancer cells.
What is the Core Technology Protected by Patent 9,561,197?
The patent primarily protects pharmaceutical compositions comprising antibodies that are characterized by their affinity and activity against PD-1 or PD-L1. Specifically, the claims define antibodies based on their ability to bind to these target proteins and, in many instances, their capacity to block the interaction between PD-1 and PD-L1. This blockade is critical for enhancing T-cell mediated immune responses against tumors [1].
Key Claim Elements
The claims within U.S. Patent 9,561,197 detail specific characteristics of the antibodies and their formulations.
- Antibody Specificity: Claims focus on antibodies that bind to human PD-1 or human PD-L1. This specificity ensures the drug targets the intended pathway in human patients.
- Blocking Activity: Many claims require the antibody to block the interaction between PD-1 and PD-L1. This functional requirement is essential for the therapeutic effect.
- Binding Kinetics: Some claims may specify binding affinity constants (KD) or dissociation rates (koff) to define the strength and duration of the antibody's interaction with its target.
- Amino Acid Sequences: Certain claims could define the antibody by its specific amino acid sequence, providing a precise molecular definition.
- Pharmaceutical Composition: The patent also covers compositions containing these antibodies, often including pharmaceutically acceptable carriers, excipients, or diluents. These formulations are designed for safe and effective administration to patients [1].
What are the Primary Therapeutic Applications Claimed?
The therapeutic applications claimed by U.S. Patent 9,561,197 center on the use of the defined antibodies in treating cancers where the PD-1/PD-L1 pathway plays a role in immune evasion.
Cancer Indications
The patent broadly covers the use of these antibodies in treating various types of cancer. This includes, but is not limited to:
- Carcinomas
- Sarcomas
- Leukemias
- Lymphomas
- Melanoma
- Lung cancer
- Kidney cancer
- Bladder cancer
- Head and neck cancer
The rationale is that by inhibiting the PD-1/PD-L1 checkpoint, the antibody can restore the anti-tumor immune response, leading to tumor regression or control [1].
How Does Patent 9,561,197 Relate to the Broader PD-1/PD-L1 Inhibitor Landscape?
U.S. Patent 9,561,197 contributes to the growing body of intellectual property surrounding PD-1 and PD-L1 inhibitors, a class of drugs that has revolutionized cancer treatment.
Competitive Landscape
The patent landscape for PD-1/PD-L1 inhibitors is highly competitive, with multiple pharmaceutical companies holding patents on various antibodies targeting this pathway. Key players in this space include:
- Merck & Co.: With its drug Keytruda (pembrolizumab), targeting PD-1.
- Bristol Myers Squibb: With its drug Opdivo (nivolumab), also targeting PD-1.
- AstraZeneca: With its drug Imfinzi (durvalumab), targeting PD-L1.
- Genentech (Roche): With its drug Tecentriq (atezolizumab), targeting PD-L1.
U.S. Patent 9,561,197, held by Pfizer, represents another proprietary claim within this crowded field. The scope of Pfizer's patent will dictate its ability to exclude competitors from making, using, selling, or importing compositions containing antibodies matching the patent's claims, particularly during the patent's term.
Patent Exclusivity and Market Impact
The granted patent provides Pfizer with a period of market exclusivity, typically 20 years from the filing date, subject to potential patent term extensions. This exclusivity is crucial for recouping substantial research and development investments and for establishing a market position for any drug product that falls under its claims. The existence of such patents influences pricing strategies, market entry timelines for new entrants, and the potential for licensing agreements or litigation [2].
What is the Status and Remaining Term of Patent 9,561,197?
Understanding the current status and remaining term of U.S. Patent 9,561,197 is vital for strategic planning related to R&D and investment.
Patent Term
- Issue Date: February 7, 2017
- Filing Date: December 17, 2013
- Original Expiration Date: December 17, 2033 (20 years from the filing date)
The patent term can be extended through mechanisms such as Patent Term Adjustment (PTA) or Patent Term Extension (PTE) if applicable. PTE can compensate for delays in regulatory review, particularly for pharmaceutical products. Any granted extensions would push the expiration date further into the future [3].
Maintenance Fees
To keep the patent in force, the patent owner must pay periodic maintenance fees to the United States Patent and Trademark Office (USPTO). These fees are due at 3.5, 7.5, and 11.5 years after the patent grant date. Failure to pay these fees results in the patent expiring prematurely. As of the latest available USPTO records, assuming maintenance fees have been paid, the patent remains in force until its original expiration date, subject to any extensions [4].
What are the Potential Implications for Generic Competition and Biosimilars?
The existence and scope of U.S. Patent 9,561,197 have direct implications for the development and launch of generic drugs or biosimilars targeting the same therapeutic pathway.
Barriers to Entry
For a biosimilar or generic manufacturer to enter the market for a drug covered by this patent, they must navigate the patent landscape. This often involves:
- Non-Infringement: Designing their product to not fall within the scope of the patent's claims. This may involve developing antibodies with different amino acid sequences, binding characteristics, or formulations that are demonstrably outside the patent's protected territory.
- Patent Challenge: Attempting to invalidate the patent through legal proceedings, such as inter partes review (IPR) at the USPTO or litigation in federal court.
- Licensing: Negotiating a license with the patent holder (Pfizer) to allow for market entry, often preceding or coinciding with patent expiration.
Biosimilar Pathway
The Biologics Price Competition and Innovation Act (BPCIA) provides an abbreviated pathway for the approval of biosimilars. However, this pathway is still subject to existing patents. Biosimilar applicants typically must provide notice to the patent holder regarding their intent to market a biosimilar and the potential for patent litigation is high. The specific claims of Patent 9,561,197 will be scrutinized to determine the extent to which they cover a potential biosimilar product referencing an antibody against PD-1 or PD-L1 [5].
What is the Patent's Intellectual Property Strategy?
Patents like U.S. Patent 9,561,197 are critical components of a pharmaceutical company's intellectual property strategy, designed to protect innovation and secure market exclusivity.
Strategic Value
- Monopoly Protection: The primary goal is to obtain a monopoly on the claimed technology for a defined period, allowing for the recoupment of R&D expenses and generation of profits.
- Blocking Competitors: The patent serves as a barrier to entry for competitors who wish to develop or market similar products.
- Licensing Opportunities: Patents can be licensed to other companies, generating revenue streams through royalties and upfront payments.
- Foundation for Future Innovation: The patent can serve as a foundation upon which further research and development can build, potentially leading to new patents for improved versions or new uses of the technology.
- Valuation and Investment: A strong patent portfolio, including key patents like 9,561,197, enhances a company's valuation and attractiveness to investors.
The precise claims of this patent define the specific boundaries of Pfizer's protection, guiding their commercialization efforts and their defensive and offensive strategies against competitors.
Key Takeaways
- U.S. Patent 9,561,197 protects pharmaceutical compositions comprising antibodies that inhibit the PD-1/PD-L1 pathway, with applications in cancer immunotherapy.
- The patent defines antibodies by their binding characteristics to PD-1 or PD-L1 and their ability to block the interaction between these proteins.
- The original expiration date for the patent is December 17, 2033, subject to potential extensions.
- This patent contributes to the competitive landscape of PD-1/PD-L1 inhibitors, influencing market exclusivity and the development of biosimilars.
- Pfizer Inc. holds the rights to this patent, which is a significant asset in their pharmaceutical IP portfolio.
FAQs
-
What is the primary mechanism of action protected by U.S. Patent 9,561,197?
The patent protects the use of antibodies that bind to and inhibit the interaction between programmed cell death protein 1 (PD-1) and its ligand (PD-L1), thereby enhancing anti-tumor immune responses.
-
Who is the assignee of U.S. Patent 9,561,197?
Pfizer Inc. is the assignee of U.S. Patent 9,561,197.
-
When does U.S. Patent 9,561,197 expire?
The patent's original expiration date, 20 years from its filing date, is December 17, 2033. This term may be extended by specific provisions.
-
Can a company develop a PD-1/PD-L1 inhibitor if it doesn't directly infringe on U.S. Patent 9,561,197?
Yes, companies can develop related inhibitors if their products do not fall within the specific claims of Patent 9,561,197. This often involves designing antibodies with different sequences or binding characteristics, or targeting different aspects of the immune pathway.
-
What are the implications of this patent for biosimilar development?
This patent creates a barrier for biosimilar developers. A biosimilar referencing a product covered by this patent must either operate outside the patent's claims, challenge its validity, or obtain a license from Pfizer.
Citations
[1] U.S. Patent No. 9,561,197 (filed Dec. 17, 2013) issued Feb. 7, 2017.
[2] U.S. Patent and Trademark Office. (n.d.). Patent Basics. Retrieved from https://www.uspto.gov/learning-and-resources/ip-program-resources/patent-basics
[3] U.S. Patent and Trademark Office. (n.d.). Patent Term and Patent Term Extension. Retrieved from https://www.uspto.gov/patents/laws/patent-term-and-patent-term-extension
[4] U.S. Patent and Trademark Office. (n.d.). Maintenance Fees. Retrieved from https://www.uspto.gov/patents/maintain
[5] U.S. Food & Drug Administration. (2020, April 14). Biosimilarity & Interchangeability. Retrieved from https://www.fda.gov/drugs/biosimilars/biosimilarity-interchangeability
